Currently predicting for Thu, 4 Jun 2026

ERAS Prediction Chart

ERAS Predictions History

Latest community submissions for ERAS.
Predictor Target Session Target Price Result Direction Accuracy Score
Mar 16, 2026 $13.86 +1.76% $13.51 X 97.41% 0
Mar 16, 2026 Bullish $13.51 X 0
Mar 9, 2026 $15.14 -2.16% $15.76 X 96.04% 0
Mar 9, 2026 $15.26 -1.35% $15.76 X 96.83% 0
Mar 9, 2026 $15.47 +0.00% $15.76 X 98.16% 0
Mar 3, 2026 $14.21 -2.18% $14.10 V 99.20% 3
Mar 3, 2026 $14.33 -1.36% $14.10 V 98.35% 1
Mar 3, 2026 Bullish $14.10 X 0
Feb 27, 2026 $13.27 -2.25% $13.66 X 97.11% 0
Feb 27, 2026 $13.38 -1.40% $13.66 X 97.95% 0
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for ERAS with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT ERASCA, INC.
Erasca
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE